TLN indirect play in Biomarker 12B markethttps://www.bccresearch.com/report/BIO061A.html
TLN, digging in the biomarker market potential... I am beginning to think that TLN management should not have sold CellCarta at all.
It's a 12B market size in 3 years.
IF TLN can hold on to this asset, TLN SP could rise just because of this sole asset.
Anyway, unamed pharma buyer isn't an idiot.
They must have seen all that I have uncovered thus far.
Amazingly stupid TLN shareholders.
Now, there is a bidder trying to dump 28000 TLN shares at 0,30$ and numerous other below him on a daily basis.
You must be desperate or out of your mind.
My advice to TLN management. GEt a PR guy with a decent background in public contact.
Do a status update and give this information out.
Basically walking analysts and shareholders by hand on this value. Otherwise, you (managemet who also happen to be-majority holder) will loose more profit.
Caprion could be a multi millions dividend generating or cash machine for TLN.
IF you sell Caprion, try to get closed to 70-80million for it. IF not, this time keep it for L-t.
Caprion could supplement cash burn and TLN could be at break even based on Caprion alone
I am now seeing a no cash problem for TLN. A no cash problem at all.